Nomura Maintains ASAHI KASEI CORP(AHKSF.US) With Hold Rating, Raises Target Price to $7.7
ASAHI KASEI CORP To Go Ex-Dividend On March 28th, 2025 With 0.1584 USD Dividend Per Share
November 1st (Eastern Time) - $ASAHI KASEI CORP(AHKSF.US)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 0.1584 USD dividend per share on June 3rd,
J.P. Morgan Maintains ASAHI KASEI CORP(AHKSF.US) With Buy Rating, Raises Target Price to $10.55
Morgan Stanley Initiates ASAHI KASEI CORP(AHKSF.US) With Hold Rating, Announces Target Price $8.52
Morgan Stanley analyst Takato Watabe initiates coverage on $ASAHI KASEI CORP(AHKSF.US)$ with a hold rating, and sets the target price at $8.38.According to TipRanks data, the analyst has a success
ASAHI KASEI CORP To Go Ex-Dividend On September 27th, 2024 With 0.1584 USD Dividend Per Share
July 9th (Eastern Time) - $ASAHI KASEI CORP(AHKSF.US)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 0.1584 USD dividend per share on
Asahi Kasei Launches Membrane System to Produce Water for Injection
On May 29, Genting Xinyao announced that its partner Calliditas Therapeutics AB (Calliditas) announced that Asahi Kasei Corp. (Asahi Kasei Corp.) proposed to acquire Calliditas at a price of 11.164 billion SEK (about 1.1 billion US dollars). The offer rep
On May 29, Genting Xinyao announced that its partner Calliditas Therapeutics AB (Calliditas) announced that Asahi Kasei Corp. (Asahi Kasei Corp.) proposed to acquire Calliditas at a price of 11.164 billion SEK (about 1.1 billion US dollars). The offer represents an 83% premium over Calliditas' closing price on May 27. Calliditas' proposed acquisition by Asahi Kasei Group will not affect the deal signed between Genting Xinyao and Calliditas
Deals of the Day-Mergers and Acquisitions
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Express News | U.S.-Listed Shares of Calliditas Therapeutics up 70.1% After Tender Offer From Asahi Kasei Corp
Asahi Kasei Offers to Buy Calliditas Therapeutics for $1.1B
Asahi Kasei Corp FY Net Y43.81B Vs Loss Y91.95B
Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada
Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development
Asahi Kasei to Highlight Sustainability, 3D Printing Filaments, Purging Compounds, and More at NPE 2024
Asahi Kasei Medical and AW Technologies Enter Exclusive Distribution Agreement for TrachFlush in Japan
Asahi Kasei Bioprocess' Massachusetts Training Center Expands 2024 Course Offerings for Career Development and Industry Training
Senseair Releases New Module, S88, for Advanced CO2 Monitoring
Pearlescent Pigment Market Size to Increase by USD 438.98 Million Between 2022 to 2027, Altana AG, Asahi Kasei Corp., BASF SE, and More Among Key Companies, Technavio
Asahi Kasei Offers Pharmaceutical Excipient Ceolus With Nitrite Concentration of 0.1 Ppm or Less